PE20030269A1 - Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas - Google Patents
Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulasInfo
- Publication number
- PE20030269A1 PE20030269A1 PE2002000595A PE2002000595A PE20030269A1 PE 20030269 A1 PE20030269 A1 PE 20030269A1 PE 2002000595 A PE2002000595 A PE 2002000595A PE 2002000595 A PE2002000595 A PE 2002000595A PE 20030269 A1 PE20030269 A1 PE 20030269A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- benzamide
- ilamine
- heteroalkyl
- haloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Abstract
SE REFIERE A COMPUESTOS CON NUCLEO (4-AMINOTIAZOL-2-ILAMINA)-BENZAMIDA DE FORMULA (I) DONDE R1 Y R2 SON H, ALQUILO, ALQUENILO, ALQUINILO, ENTRE OTROS O JUNTOS CON N-C=O Y DOS ATOMOS DE C ADYACENTES AL FENILO FORMAN UN ANILLO DE 5 O 6 MIEMBROS FUSIONADA CON FENILO Y PUEDE O NO SUSTITUIRSE CON ALQUILO, HETEROALQUILO, HALOALQUILO, HALOARILO, ENTRE OTROS; O R1 Y R2 JUNTO CON EL ATOMO DE N FORMAN UN MONOCICLICO O POLICICLICO QUE PUEDE CONTENER DE UNO A TRES HETEROATOMOS ADICIONALES, SIENDO NO SUSTITUIDO O SUSTITUIDO CON UNO O MAS ALQUILO, HETEROALQUILO, HALOALQUILO, HALOARILO, ENTRE OTROS; R3 ES UN ARILO HETEROARILO, ALQUILO O CICLOALQUILO, NO SUSTITUIDO O SUSTITUIDO CON UNO O MAS ALQUILO, HETEROALQUILO, HALOALQUILO, HALOARILO, ENTRE OTROS; Y ES H, ALQUILO, HETEROALQUILO, HALOALQUILO, HALOCICLOALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 4-(4-AMINA-5-(2,6-DIFLUORO-BENZOIL)-TIAZOL-2-ILAMINA)-N-(2-DIMETILPROPIL)-BENZAMIDA, 4-(4-AMINA-5-(2,6-DIFLUORO-BENZOIL)-TIAZOL-2-ILAMINA)-N-(2-DIMETILAMINA-METIL-ETIL)-BENZAMIDA, 4-(4-AMINA-5-(2,6-DIFLUORO-BENZOIL)-2-ILAMINA)-N-(1-ETIL-PIRROLIDIN-2-ILMETIL)-BENZAMIDA, ENTRE OTROS. LOS COMPUESTOS SON INHIBIDORES DE PROTEINAQUINASA, MODULANDO LA PROLIFERACION CELULAR Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE CRECIMIENTO DE TUMOR, ANGIOGENESIS, INFECCION VIRAL, ENFERMEDAD AUTOINMUNE O DESORDEN NEURODEGENERATIVO
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30367901P | 2001-07-06 | 2001-07-06 | |
US30527401P | 2001-07-13 | 2001-07-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20030269A1 true PE20030269A1 (es) | 2003-04-16 |
Family
ID=26973595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2002000595A PE20030269A1 (es) | 2001-07-06 | 2002-07-02 | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas |
Country Status (13)
Country | Link |
---|---|
US (1) | US6720346B2 (es) |
EP (1) | EP1438046A4 (es) |
JP (1) | JP2005521631A (es) |
AU (1) | AU2002354801A1 (es) |
BR (1) | BR0210874A (es) |
CA (1) | CA2452609A1 (es) |
HN (1) | HN2002000156A (es) |
MX (1) | MXPA04000069A (es) |
PA (1) | PA8550101A1 (es) |
PE (1) | PE20030269A1 (es) |
SV (1) | SV2003001148A (es) |
UY (1) | UY27370A1 (es) |
WO (1) | WO2003004467A2 (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6495550B2 (en) * | 1999-08-04 | 2002-12-17 | Icagen, Inc. | Pyridine-substituted benzanilides as potassium ion channel openers |
CA2378241A1 (en) | 1999-08-04 | 2001-02-15 | Icagen, Inc. | Benzanilides as potassium channel openers |
AU2002322280A1 (en) | 2001-06-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
AU2003282231A1 (en) * | 2002-08-09 | 2004-02-25 | Pfizer Inc. | Antiproliferative 2-(heteroaryl)-aminothiazole compounds, pharmaceutical compositions and methods for their use |
ATE479667T1 (de) * | 2003-02-06 | 2010-09-15 | Bristol Myers Squibb Co | Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis |
JP2006517234A (ja) | 2003-02-10 | 2006-07-20 | アムジエン・インコーポレーテツド | バニロイド受容体リガンドおよび治療におけるこれらのリガンドの使用 |
MXPA05008520A (es) * | 2003-02-12 | 2005-10-20 | Pfizer | Derivados de 2-(sulfo-fenil)-aminotiazol antiproliferativos. |
BRPI0410905A (pt) | 2003-06-03 | 2006-06-27 | Novartis Ag | inibidores de p-38 |
CA2526455C (en) | 2003-06-26 | 2012-10-09 | Novartis Ag | 5-membered heterocycle-based p38 kinase inhibitors |
US20050026966A1 (en) * | 2003-07-30 | 2005-02-03 | Agouron Pharmaceuticals, Inc. | Process and chiral amine intermediates useful for preparation of antiproliferative 2,4-diaminothiazole amide compounds |
WO2005028624A2 (en) * | 2003-09-15 | 2005-03-31 | Plexxikon, Inc. | Molecular scaffolds for kinase ligand development |
NZ548884A (en) * | 2004-01-30 | 2010-06-25 | Ab Science | 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors |
EP1732905A1 (en) * | 2004-03-31 | 2006-12-20 | Lexicon Genetics Incorporated | 2-aminomethylthiazole-5-carboxamides as protein kinase modulators |
WO2005102326A2 (en) * | 2004-04-23 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating renal diseases |
US7618981B2 (en) * | 2004-05-06 | 2009-11-17 | Cytokinetics, Inc. | Imidazopyridinyl-benzamide anti-cancer agents |
US7423053B2 (en) * | 2004-07-15 | 2008-09-09 | Hoffmann-La Roche Inc. | 4-Aminothiazole derivatives |
JP4652079B2 (ja) * | 2005-02-15 | 2011-03-16 | 花王株式会社 | 2,2−二置換エチレンジアミン誘導体の製造方法 |
CA2600869A1 (en) * | 2005-03-18 | 2006-09-28 | The Regents Of The University Of California | Compounds having activity in correcting mutant-cftr processing and uses thereof |
AP2358A (en) | 2005-05-09 | 2012-01-30 | Achillion Pharmaceuticals Inc | Thiazole compounds and methods of use. |
CA2645731A1 (en) | 2006-03-15 | 2007-09-27 | Wyeth | N-substituted-azacyclylamines as histamine-3 antagonists |
ATE533744T1 (de) | 2006-05-19 | 2011-12-15 | Wyeth Llc | N-benzoypyrrolidin-3-ylamine als histamin-3 antagonisten |
PE20081152A1 (es) | 2006-10-06 | 2008-08-10 | Wyeth Corp | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 |
JP5649822B2 (ja) * | 2006-11-23 | 2015-01-07 | チバ ホールディング インコーポレーテッドCiba Holding Inc. | N−アリル立体障害性第三アミンの製造方法 |
ES2567179T3 (es) * | 2007-01-31 | 2016-04-20 | Basf Se | Colorantes catiónicos |
GB0705656D0 (en) * | 2007-03-23 | 2007-05-02 | Addex Pharmaceuticals Sa | Novel compounds E1 |
CL2008002088A1 (es) | 2007-07-16 | 2008-09-05 | Wyeth Corp | Compuestos derivados de fenilo sustituido, moduladores del receptor de histamina 3; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de trastornos cognitivos tales como demencia, alzheimer, entre otros. |
WO2009148961A2 (en) * | 2008-05-29 | 2009-12-10 | Wisconsin Alumni Research Foundation | Drugs to prevent hpv infection |
SG196784A1 (en) * | 2008-12-03 | 2014-02-13 | Scripps Research Inst | Stem cell cultures |
JP5212656B2 (ja) * | 2009-09-02 | 2013-06-19 | 日産化学工業株式会社 | イソチオシアナト化合物の製造方法 |
US9102602B2 (en) | 2010-11-29 | 2015-08-11 | Nissan Chemical Industries, Ltd. | Method for producing isothiocyanate compound |
WO2013089689A1 (en) * | 2011-12-13 | 2013-06-20 | Kneller Bruce W | Constituent of desmodium elegans and methods of use |
WO2015199206A1 (ja) * | 2014-06-27 | 2015-12-30 | 塩野義製薬株式会社 | Trpv4阻害活性を有する6員環誘導体 |
EP3601250A4 (en) * | 2017-03-27 | 2020-11-25 | Pharmakea, Inc. | APOPTOSIS SIGNAL REGULATION KINASE 1 (ASK 1) INHIBITOR COMPOUNDS |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE262902T1 (de) | 1994-11-10 | 2004-04-15 | Millennium Pharm Inc | Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose |
EP0816362A4 (en) | 1995-03-22 | 1998-07-08 | Taisho Pharmaceutical Co Ltd | THIAZOLE DERIVATIVES |
EP0888310B1 (en) | 1996-03-15 | 2005-09-07 | AstraZeneca AB | Cinnoline derivatives and use as medicine |
TW513418B (en) | 1996-07-31 | 2002-12-11 | Otsuka Pharma Co Ltd | Thiazole derivatives, their production and use |
ES2267873T3 (es) * | 1997-10-27 | 2007-03-16 | Agouron Pharmaceuticals, Inc. | Derivados de 4-aminotiazol, su preparacion y uso como inhibidores de kinasas dependientes de ciclina. |
HUP0102101A3 (en) | 1997-11-10 | 2002-11-28 | Bristol Myers Squibb Co | Protein tyrosine kinase inhibitor benzothiazole derivatives and pharmaceutical compositions containing them |
US6040321A (en) | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
FR2780058B1 (fr) | 1998-06-17 | 2001-03-09 | Rhodia Chimie Sa | Emulsion aqueuse de silane pour l'hydrofugation de materiaux de construction |
CA2337755C (en) | 1998-09-18 | 2008-07-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
GB9823871D0 (en) | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
US6756374B2 (en) | 2001-01-22 | 2004-06-29 | Hoffmann-La Roche Inc. | Diaminothiazoles having antiproliferative activity |
-
2002
- 2002-06-26 HN HN2002000156A patent/HN2002000156A/es unknown
- 2002-07-02 PE PE2002000595A patent/PE20030269A1/es not_active Application Discontinuation
- 2002-07-04 SV SV2002001148A patent/SV2003001148A/es not_active Application Discontinuation
- 2002-07-04 UY UY27370A patent/UY27370A1/es not_active Application Discontinuation
- 2002-07-05 EP EP02782499A patent/EP1438046A4/en not_active Withdrawn
- 2002-07-05 CA CA002452609A patent/CA2452609A1/en not_active Abandoned
- 2002-07-05 JP JP2003510635A patent/JP2005521631A/ja not_active Withdrawn
- 2002-07-05 US US10/190,219 patent/US6720346B2/en not_active Expired - Fee Related
- 2002-07-05 WO PCT/US2002/021280 patent/WO2003004467A2/en active Application Filing
- 2002-07-05 MX MXPA04000069A patent/MXPA04000069A/es unknown
- 2002-07-05 AU AU2002354801A patent/AU2002354801A1/en not_active Abandoned
- 2002-07-05 BR BRPI0210874-7A patent/BR0210874A/pt not_active IP Right Cessation
- 2002-07-08 PA PA20028550101A patent/PA8550101A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2003004467A2 (en) | 2003-01-16 |
EP1438046A2 (en) | 2004-07-21 |
US20030225147A1 (en) | 2003-12-04 |
AU2002354801A1 (en) | 2003-01-21 |
EP1438046A4 (en) | 2004-10-20 |
HN2002000156A (es) | 2003-11-27 |
WO2003004467A3 (en) | 2004-05-06 |
MXPA04000069A (es) | 2004-05-21 |
SV2003001148A (es) | 2003-03-18 |
BR0210874A (pt) | 2006-10-24 |
UY27370A1 (es) | 2003-04-30 |
PA8550101A1 (es) | 2003-09-05 |
JP2005521631A (ja) | 2005-07-21 |
US6720346B2 (en) | 2004-04-13 |
CA2452609A1 (en) | 2003-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20030269A1 (es) | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas | |
AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
ATE380818T1 (de) | Piperazine-substituierte aryl-benzodiazepinen und ihre verwendung als dopaminrezeptor-antagonisten zur behandlung von psychose | |
PE20020354A1 (es) | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) | |
CA2423103A1 (en) | N-acylsulfonamide apoptosis promoters | |
AR034253A1 (es) | Compuestos activadores de glucoquinasa que contienen hidantoina sustituida, un procedimiento para su preparacion, composiciones farmaceuticas, procedimientos para su preparacion, empleo de los mismos para la preparacion de medicamentos | |
CR8505A (es) | Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
CO5261605A1 (es) | Compustos farmaceuticos | |
PE20050018A1 (es) | Compuesto pentaciclico heteroaromatico como inhibidor de la proteina tirosina fosfatasa 1b (ptb1b) | |
SE9703377D0 (sv) | New compounds | |
AR044909A1 (es) | Derivados de tiazolilpiperidina, procesos para su preparacion, composiciones farmaceuticas que los comprenden y aplicaciones de dichos derivados en el tratamiento de hipertrigliceridemia , hipercolesterolemia y dislipidemia | |
CO5251464A1 (es) | Inhibidores de n-(5-(((5-alquil-2-oxazolil)metil)tio)-2- tiazolil)-carboxamida de cinasas dependientes de ciclina | |
MX9206939A (es) | Derivados de piperazina, procedimiento para su preparacion y composicion farmaceutica que los comprende | |
AR038818A1 (es) | Compuesto de piperidina, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion | |
CO5720994A2 (es) | Derivados sustituidos del pirrol | |
IT1171880B (it) | Derivati di 2-ammino-3-acilammino-6-benzilammino-piridina aventi azione antiepilettica e procedimento per la loro produzione | |
DE3874576T2 (de) | 4-(4-(4-(4-((2-(2,4-difluorophenyl)-2-(1h-azolylmethyl)-1,3-dioxolan-4-yl)-methoxy)phenyl)-1-piperazinyl)phenyl)triazolone. | |
NO983493L (no) | Nye benzimidazol-, benzoksazol- og benzotiazolforbindelser, fremgangsmÕte ved fremstilling derav og farmas°ytiske sammensetninger inneholdende slike | |
AR042362A1 (es) | Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen | |
SE9703378D0 (sv) | New compounds | |
PT83725B (pt) | Processo para preparacao de novos derivados da 3-oxadiol-beta-carbolina e 3-carboxilato-beta-carbolina e de composicoes farmaceuticas que os contem | |
AR124973A1 (es) | Nuevos derivados de pirimidina-2-il sulfonamida | |
ATE94560T1 (de) | L-prolin-derivate, deren herstellung und deren biologische anwendungen. | |
AR037459A1 (es) | Antagonistas vi del receptor ccr-3 | |
DK0652874T3 (da) | 2-heterocycliske-5-hydroxy-1,3-pyrimidiner der er nyttige som antiinflammatoriske midler |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |